Who
Thomas James Doyle
SVP, Finance & Accounting
Company insider
Files Form 4 as: SVP, Finance & Accounting, Kura Oncology.
In numbers
- Trades disclosed
- 38
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $411K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 Feb 2022
- Last trade
- 28 Sep 2026
- Last filed
- 29 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $48K4,607 at $10.50 | filing |
| 28 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $48K4,607 at $10.50 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $19K2,226 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $9,4251,114 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $5,880695 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $19K2,226 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $7,454881 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $19K2,226 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $9,4241,114 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $5,880695 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $19K2,226 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $7,453881 at $8.46 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —21,250 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —21,250 at $0.00 | filing |
| 14 Nov 2025filed 14 Nov 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $51K4,539 at $11.18 | filing |
| 13 Nov 2025filed 14 Nov 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —24,967 at $0.00 | filing |
| 29 Sep 2025filed 29 Sep 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $41K4,541 at $8.94 | filing |
| 27 Sep 2025filed 29 Sep 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —24,966 at $0.00 | filing |
News
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesKURA · manilatimes.net · 13 Oct 2026Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in DiabetesKURA · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Thomas James Doyle; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.